HanAll BioPharma

009420 · KOSPI

Public Market Listing

009420KOSPI

KOSPI primary exchange listing

Live quotes, historical charts, and market capitalization for HanAll BioPharma are available on Yahoo Finance.

View quote & market cap on Yahoo Finance ↗

External market data link · No third-party exchange redistribution

Assets

(2 total)
2Total Assets
0Approved
1Phase 3 / Filed
1Phase 1–2 / Early
6Diseases
Quick filter:
Showing 2 of 2 assets
Target & Modality
Phase 3
FcRnMonoclonal antibody
Rheumatoid ArthritisMyasthenia GravisGraves' DiseaseChronic Inflammatory Demyelinating PolyneuropathySjögren's Disease
Phase 1
Nurr1 (NR4A2, nuclear orphan receptor)Small molecule
Parkinson's Disease

Upcoming events

(7 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (3)
May 2027 (1)
ImeroprubartPhase 2Graves' Disease
Est. primary completion 2027-05 · NCT07018323 · CT.gov ↗
What to watch
September 2027 (1)
ImeroprubartPhase 2Rheumatoid Arthritis
Est. primary completion 2027-09 · NCT06754462 · CT.gov ↗
What to watch
December 2027 (1)
ImeroprubartPhase 3Generalized Myasthenia Gravis
Est. primary completion 2027-12 · NCT07039916 · CT.gov ↗
What to watch
2028 (3)
June 2028 (1)
ImeroprubartPhase 2Graves' Disease
Est. primary completion 2028-06 · NCT06727604 · CT.gov ↗
What to watch
July 2028 (1)
ImeroprubartPhase 2Primary Sjögren's Syndrome
Est. primary completion 2028-07 · NCT06979531 · CT.gov ↗
What to watch
August 2028 (1)
ImeroprubartPhase 2Chronic Inflammatory Demyelinating Polyneuropathy
Est. primary completion 2028-08 · NCT07032662 · CT.gov ↗
What to watch
2030 (1)
March 2030 (1)
ImeroprubartPhase 2Graves' Disease
Est. primary completion 2030-03 · NCT07286006 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(2)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Coming up

November 2026Topline resultImeroprubartRandomized withdrawal period (Period 2) in difficult-to-treat RA met its primary endpoint

Recent

23 September 2026Topline resultIMVT-1402IMVT-1402 CLE proof-of-concept study misses primary endpoint; CLE development stopped
Immunovant, Inc. · Source ↗

Financial reports

Annual history (1 year)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY$11M——<$0.1Mreport ↗